Home » Drug Information » FDA Approved Drugs » 1997
Medical Areas: Endocrinology | Nephrology
View By:YearCompanyConditionsTherapeutic AreasDrug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Fujisawa Healthcare
Approval Status: Approved April 1997
Treatment Area: kidney transplant rejection
Prograf has been approved for use as an immunosuppressive for
the prevention of organ rejection in kidney transplant recipients.
It is manufactured in capsule and injection form. Previously,
Prograf has been used since 1994 for the prophylaxis of rejection
in liver transplants.
Adverse effects associated with Prograf include tremor,
hypertension, hypophosphatemia, infection, creatinine increase,
headache, and diarrhea. New onset post-transplant diabetes mellitus
(PTDM) was seen in 20% of Prograf-treated kidney transplant
patients. The percentage of PTDM patients that remained insulin
dependent at the two year post-transplant mark declined to 11%.